Metformin sensitizes endometrial cancer cells even progestin-resistant EC cells to progestin by promoting progesterone receptor (28), downregulating glyoxalase I expression (29), downregulating glyoxalase I expression (30). This evidence concerns the gene GLO1 and endometrial cancer.